Brachyury: Strategies for Drugging an Intractable Cancer Therapeutic Target
Helena Robinson1, Ramsay J McFarlane1, Jane A Wakeman1
1North West Cancer Research Institute, School of Medical Sciences, Bangor University, Deiniol Road, Bangor, Gwynedd LL57 2UW, UK.
Trends in Cancer
|March 27, 2020
Summary
New drug discovery approaches target cancer molecules. Brachyury is a promising target for chordoma, a rare bone cancer, with potential applications in other cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Cancer-specific molecules offer significant therapeutic potential.
- Brachyury is identified as a key target in rare bone cancer, chordoma.
Purpose of the Study:
- To review recent advancements in targeting Brachyury for chordoma treatment.
- To explore the broader implications of Brachyury targeting for other cancer types.
Main Methods:
- Literature review of recent studies on Brachyury and chordoma.
- Analysis of emerging therapeutic strategies targeting the Brachyury protein.
Main Results:
- Brachyury is a validated target in chordoma, with ongoing drug development.
- Targeting Brachyury shows promise beyond chordoma, potentially applicable to other malignancies.
Conclusions:
- Targeting Brachyury represents a novel therapeutic strategy for chordoma.
- Advances in Brachyury-targeted therapies may extend to more prevalent cancer types, broadening treatment options.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
01:26Targets for Drug Action: Overview
9.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.8K
02:38Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K